|
|
 |
ASPARTAME Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AKYNZEO Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AMMONIUM GLYCYRRHIZATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ANHYDROUS CITRIC ACID Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
XTAMPZA ER Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
BENZETHONIUM CHLORIDE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM HYDROXIDE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ACTOPLUS MET Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ASCORBIC ACID Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|